Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

(2011) J. Jakubikova et al.   BLOOD

New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

(2010) Y. Dai et al.   CLINICAL CANCER RESEARCH

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

In vitro and In vivo Radiosensitization with AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase

(2009) E. J. Chung et al.   CLINICAL CANCER RESEARCH

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells

(2008) Y. Dai et al.   BLOOD

Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate

(2008) Y. Dai et al.   BLOOD

KLF4 is a FOXO target gene that suppresses B cell proliferation

(2008) I. Yusuf et al.   INTERNATIONAL IMMUNOLOGY

Expanded Roles for Chk1 in Genome Maintenance

(2008) Greg H. Enders   JOURNAL OF BIOLOGICAL CHEMISTRY

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

(2008) S. D. Zabludoff et al.   MOLECULAR CANCER THERAPEUTICS

Regulation of DNA repair throughout the cell cycle

(2008) Dana Branzei et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY